Back to search
FDAFDA · Food and drugs·Recall number D-0210-2025

Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US Inc., Northbrook, IL 60062, NDC 0469-0647-73.

Published February 5, 2025 · Recall initiated: December 23, 2024

Summary

FDA records drug Class I recall D-0210-2025, published February 5, 2025 and initiated December 23, 2024. Recalling firm: Astellas Pharma US Inc.; Status: Ongoing; Reported quantity: 3,500 30-count bottles; Lot: Lot# 0R3092A, EXP 03/31/2026. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

What to do

Voluntary: Firm initiated · Press Release

Get an email if ASTAGRAF XL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ASTAGRAF XL
Manufacturer
Astellas Pharma US Inc.
Distributor
Nationwide in the USA
Lot
Lot# 0R3092A, EXP 03/31/2026
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US Inc., Northbrook, IL 60062, NDC 0469-0647-73. recalled?

Yes. FDA published recall D-0210-2025 on February 5, 2025. Reported hazard: Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

What should I do if I have this product?

Voluntary: Firm initiated · Press Release

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ASTAGRAF XL.